• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Nameassay,hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
PMA NumberP000012
Supplement NumberS009
Date Received02/15/2006
Decision Date06/16/2006
Product Code
MZP[ Registered Establishments with MZP ]
Advisory Committee Microbiology
Supplement Typereal-time process
Supplement Reason change design/components/specifications - other
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the extension of the shelf life to 24 months of the hcv master mix, version 2. 0, a component of the cobas amplicor hcv test, v2. 0. The device, as modified, will be marketed under the trade name cobas amplicor hcv test, v2. 0 and is indicated for the qualitative detection of hcv rna in human serum or plasma from blood collected in edta (edta plasma). The test detects by reverse transcribing target hcv rna in complimentary dna (cdna), amplifying cdna by polymerase chain reaction (pcr), hybridizing amplified cdna with an oligonucleotide probe that binds enzyme, and catalyzing conversion of substrate to a colored product that is recognized by the cobas amplicor analyzer. The cobas amplicor hcv test, v2. 0 is indicated for patients who have evidence of liver disease and antibody evidence of hcv infection, and who are suspected o be actively infected with hcv.